YORK, Nov. 2, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today announced that it will be attending Bio-Europe, the largest
biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.
Actinium is advancing a pipeline of differentiated,
clinical-stage targeted radiotherapeutics including Iomab-B for
bone marrow transplant conditioning, which met the primary endpoint
in the Phase 3 SIERRA trial and is being prepared for a BLA filing,
Iomab-ACT for conditioning prior to cell and gene therapy and
Actimab-A as a therapeutic for relapsed or refractory acute myeloid
leukemia that has shown backbone therapy potential in combinations.
Actinium is also advancing novel solid tumor programs leveraging
its industry leading experience with the alpha-particle payload
Actinium-225 and intellectual property including linker technology
and Actinium-225 manufacturing.
Members of Actinium's senior leadership team will be available
for one-on-one meetings during the in-person meeting as well as the
digital partnering taking place November
14-15, 2023. To request a meeting with Actinium through
Interested parties may also contact the Company directly to
schedule in person or virtual meetings by emailing Actinium.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other blood
cancers and next generation conditioning candidate Iomab-ACT to
improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma for
solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid
tumors, and several internal programs in solid tumors. Actinium
holds more than 220 patents and patent applications.
For more information, please visit:
View original content to download
SOURCE Actinium Pharmaceuticals, Inc.